Overall breast cancer incidence · women with above‐average risk of developing breast cancer
Tamoxifen probably leads to lower overall breast cancer incidence compared with placebo (moderate certainty).
1 finding from 1 review
Severe toxicity · women with above‐average risk of developing breast cancer
Tamoxifen probably leads to higher severe toxicity compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Breast cancer mortality ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Incidence of a secondary primary breast cancer (e.g. in the contralateral breast) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)/unknown) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Prevention: incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor) or not receiving endocrine therapy…
1 finding from 1 review
OHSS · ovulation induction in polycystic ovarian syndrome
1 finding from 1 review
Clinical pregnancy rate · ovulation induction in polycystic ovarian syndrome
It is very uncertain whether antioestrogen changes clomiphene citrate plus tamoxifen versus clomiphene citrate ‐… compared with antioestrogen (very low certainty).
2 findings from 1 review
Live birth rate · ovulation induction in polycystic ovarian syndrome
Antioestrogen showed no clear difference in clomiphene citrate versus tamoxifen ‐ Live birth rate compared with antioestrogen (low certainty).
1 finding from 1 review
Miscarriage · ovulation induction in polycystic ovarian syndrome
Antioestrogen showed no clear difference in clomiphene citrate versus tamoxifen ‐ Miscarriage rate compared with antioestrogen (low certainty).
1 finding from 1 review
Multiple pregnancy · ovulation induction in polycystic ovarian syndrome
It is very uncertain whether antioestrogen changes clomiphene citrate versus tamoxifen ‐ Multiple pregnancy compared with antioestrogen (very low certainty).
1 finding from 1 review
Endometrial Polyps · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to lower endometrial polyps compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Endometrial Hyperplasia · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to lower endometrial hyperplasia compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Endometrial cancer · endometrial protection in women with breast cancer on adjuvant tamoxifen
1 finding from 1 review
Fibroids · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in fibroids compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Abnormal Vaginal Bleeding or Spotting · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance probably leads to higher abnormal vaginal bleeding or spotting compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review
Breast cancer recurrence · endometrial protection in women with breast cancer on adjuvant tamoxifen
The LNG‐IUS with endometrial surveillance showed no clear difference in breast cancer recurrence compared with endometrial surveillance alone (moderate certainty).
1 finding from 1 review